Caredx reports second quarter 2022 results

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) — the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today reported financial results for the second quarter ended june 30, 2022. recent highlights: delivered 45,000 patient test results, representing growth of 21% compared to second quarter of 2021 achieved revenue of $80.6 million, increasing 9%
CDNA Ratings Summary
CDNA Quant Ranking